Enrichment of KRAS, BRAF and MAP2K1 activating mutations were observed in CLL patients who did not respond to PI3K inhibitors, and persistent ERK activation was shown to mediate PI3K inhibitor resistance in CLL [102]. This evidence concerns the gene MAP2K1 and B-cell chronic lymphocytic leukemia.